Discover
Tremfya (guselkumab) / J&JThe Lancet simultaneously publishes two phase 3 studies detailing comprehensive efficacy and safety of Tremfya (guselkumab), a first-in-class IL-23 p19 subunit inhibitor, in psoriatic arthritis (Businesswire) - Apr 6, 2020 - P3, N=383; Discover-1 (NCT03162796); P3, N=383; Discover-2 (NCT03158285); Sponsor: Janssen Research & Development, LLC; "The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that The Lancet has published comprehensive data from DISCOVER-1 and -2, two Phase 3 studies evaluating the safety and efficacy of TREMFYA® (guselkumab) for the treatment of adults with active psoriatic arthritis (PsA). These are the first publications from a Phase 3 programme reporting safety and efficacy results in active PsA for an antibody with this mechanism of action.... Results published in The Lancet show that, at week 24, the primary endpoints achieved statistical significance in both studies. Results of secondary endpoints were also reported."
Ilumya (tildrakizumab-asmn) / Sun Pharma, AlmirallEfficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) (clinicaltrials.gov) - Apr 13, 2020 - P3; N=292; Not yet recruiting; Sponsor: Sun Pharma Global FZE; N=50 --> 292
Ilumya (tildrakizumab-asmn) / Sun Pharma, AlmirallEfficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) (clinicaltrials.gov) - Apr 13, 2020 - P3; N=472; Not yet recruiting; Sponsor: Sun Pharma Global FZE; N=200 --> 472
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimA Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (clinicaltrials.gov) - Apr 9, 2020 - P3; N=880; Recruiting; Sponsor: AbbVie; Trial primary completion date: Oct 2020 --> Jan 2021
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimA Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (clinicaltrials.gov) - Apr 7, 2020 - P3; N=880; Recruiting; Sponsor: AbbVie; Trial completion date: Dec 2024 --> Jul 2024; Trial primary completion date: Jan 2021 --> Oct 2020
BI 730357 / Boehringer IngelheimA Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is (clinicaltrials.gov) - Apr 9, 2020 - P2; N=87; Active, not recruiting; Sponsor: Boehringer Ingelheim; Recruiting --> Active, not recruiting; N=180 --> 87
Cosentyx (secukinumab) / NovartisEffect of Secukinumab in the Treatment of Psoriatic Arthritis (clinicaltrials.gov) - Apr 9, 2020 - P2; N=30; Completed; Sponsor: University of Liverpool; Active, not recruiting --> Completed; N=19 --> 30
